Yoomi Lee, MD
Medical Oncology · Alexandria, VANPI 1720262611
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,178 of the $1,324 with a category attached, or 89.0%. It is spread thinly across 29 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,262 and has fallen 98.6% since, to $18 in 2022.
Across 68 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$314
- Pfizer$132
- E.r. Squibb & Sons, L.L.C.$131
- Genentech USA, Inc.$112
- Novartis$84
- Astellas Pharma US Inc$51
- plus $501 from 23 others
What the payments were for
- Food & beverage$1,17889%
- Education$14611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 11 | $314 |
| Pfizer | 9 | $132 |
| E.r. Squibb & Sons, L.L.C. | 7 | $131 |
| Genentech USA, Inc. | 6 | $112 |
| Novartis | 4 | $84 |
| Astellas Pharma US Inc | 3 | $51 |
| EMD Serono, Inc. | 2 | $50 |
| Amgen | 2 | $37 |
| AstraZeneca | 2 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $31 |
| Seagen Inc. | 2 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Taiho Oncology, Inc. | 1 | $25 |
| Mylan Institutional Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $23 |
| Bayer | 1 | $21 |
| AbbVie | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $18 |
| Beigene USA, Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
| Merck | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Incyte Corporation | 1 | $12 |
| Lexicon Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,324 in reported general payments places this provider in the 55th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 35 | $64,481 |
| EliquisApixaban | 62 | $63,504 |
| Dexamethasone | 44 | $634 |
| Ondansetron Hcl | 44 | $594 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 42 | $463 |
| Ondansetron OdtOndansetron | 20 | $415 |
| Prochlorperazine Maleate | 32 | $415 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 35 | $402 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $337 |
| Oxycodone Hcl | 15 | $236 |
| Pantoprazole Sodium | 14 | $164 |
| Potassium Chloride | 11 | $108 |
| Metoclopramide Hcl | 13 | $102 |
| Gabapentin | 12 | $68 |
| Prednisone | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $21 | $64,48135 claims |
| PfizerEliquis | $132 | $63,50462 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Alexandria
- Valerie MartinAlexandria$373
- Janakiraman SubramanianFairfax$562K
- Alexander SpiraFairfax$533K
- Robert DreicerCharlottesville$296K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Jeanny Aragon-ChingFalls Church$194K
- Nagla Abdel KarimFairfax$131K
- John McCartyRichmond$97K
- Keri MaherRichmond$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.